Clinical outcome measures of specific immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 9, Issue 3, 2009, Pages 208-213

  Pfaar, Oliver ^a   Anders, Clemens ^a   Klimek, Ludger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allergic rhinitis; Clinical studies; Outcome parameters; Quality of life; Specific immunotherapy

Indexed keywords

ANTIALLERGIC AGENT; BUDESONIDE; CELL ADHESION MOLECULE; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE; GAMMA INTERFERON; HYMENOPTERA VENOM; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 5; LEUKOTRIENE;

ALLERGIC RHINITIS; ASTHMA; CHEST TIGHTNESS; CLINICAL ASSESSMENT; CLINICAL TRIAL; COUGHING; CYTOKINE RELEASE; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DYSPNEA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METHODOLOGY; NASAL PRURITUS; NOSE CONGESTION; NOSE PROVOCATION TEST; OCULAR PRURITUS; ORGANIZATION; OUTCOME ASSESSMENT; PHYSICIAN; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; RHINOCONJUNCTIVITIS; RHINORRHEA; SCORING SYSTEM; SHORT FORM 36; SKIN TEST; SLEEP; SNEEZING; SPIROMETRY; SYMPTOM; TREATMENT RESPONSE; VALIDATION STUDY; WHEEZING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANTIGENS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; ENDPOINT DETERMINATION; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 68049142930     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32832aef57     Document Type: Review

References (40)

1. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997. Allergy 1998; 53 (Suppl 44):1-42.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86):8-160. Latest GALEN update on SIT.
3. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-324. Important WAO update on the methodology of trials in SIT.
4. Kleine-Tebbe J, Bergmann KC, Friedrichs F, et al. Specific immunotherapy (hyposensitization) for IgE mediated allergic diseases. Allergo J 2006; 15:56-74.
5. Ciprandi G, Klersy C, Cirillo I, Marseglia GL. Quality of life in allergic rhinitis: relationship with clinical, immunological, and functional aspects. Clin Exp Allergy 2007; 37:1528-1535. A study on the importance of quality of life measures for outcome measures of clinical trials and the correlation with other parameters.
6. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases: European Medicines Agency (EMEA). Committee for Medicinal Products of Human Use; 2008. Report No. CHMP/EWP/18504/2006.
7. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21:77-83.
8. Baiardini I, Pasquali M, Giardini A, et al. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy 2003; 58:289-294.
9. Mosges R, Schmalz P, Koberlein J, et al. The RHINASTHMA-Quality of Life Scale German Adapted Version: validation of a new disease specific quality of life scale for patients suffering from allergic rhinitis and bronchial hyperreactivity. HNO 2007; 55:357-364.
10. Prasad M, Wahlqvist P, Shikiar R, Shih YC. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 2004; 22:225-244.
11. Pfaar O, Klimek L. Clinical outcome measures of specific immunotherapy. Allergo J 2007; 16:576-581.
12. Food and Drug Administration, Center for Drug Evaluation and Research. Allergic rhinitis: clinical development programs for drug products - guidance for industry. Food and Drug Administration, Center for Drug Evaluation and Research; 2000.
13. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-1345.
14. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:160-166. Recently published large pivotal trial on SLIT with grass-pollen tablets in children.
15. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-809.
16. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007; 62:954-957.
17. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167-173. Recently published large pivotal trial on SLIT with grass-pollen tablets in children.
18. Malling HJ. Criteria for clinical efficacy: readout and monitoring of clinical studies. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2003:119-123.
19. Green RH, Pavord ID. Leukotriene antagonists and symptom control in chronic persistent asthma. Lancet 2001; 357:1991-1992.
20. Virchow C. Asthma, allergic rhinitis, sinusitis: concept of the 'united airways'. HNO 2005; 53:16-20.
21. Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006; 97:419-428.
22. Fisher L,Ghaffari G, Davies M, Craig T. Effects of poor sleep in allergic rhinitis. Curr Opin Allergy Clin Immunol 2005; 5:11-16.
23. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002; 57:586-591.
24. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305:160-164.
25. Stewart M. The Medical Outcomes Study 36-item short-form health survey (SF-36). Aust J Physiother 2007; 53:208.
26. Carver DJ, Chapman CA, Thomas VS, et al. Validity and reliability of the Medical Outcomes Study Short Form-20 questionnaire as a measure of quality of life in elderly people living at home. Age Ageing 1999; 28:169-174.
27. Majani G, Baiardini I, Giardini A, et al. Health-related quality of life assessment in young adults with seasonal allergic rhinitis. Allergy 2001; 56:313-317.
28. Kremer B, Klimek L, Bullinger M, Mosges R. Generic or disease-specific quality of life scales to characterize health status in allergic rhinitis? Allergy 2001; 56:957-963.
29. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47:76-83.
30. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999; 14:32-38.
31. Barley EA, Quirk FH, Jones PW. Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Respir Med 1998; 92:1207-1214.
32. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000; 30:132-140.
33. Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med 1995; 41:1359-1366.
34. Didier A, Melac M, Montagut A, et al. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 2009; 64:166-171. Pivotal trial on SLIT with grass-allergen tablets revealing the correlation of primary and secondary outcome measures in clinical trials on SIT.
35. Riechelmann H, Bachert C, Goldschmidt O, et al. Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology. Laryngorhinootologie 2003; 82:183-188.
36. Akerlund A, Andersson M, Leflein J, et al. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol 2005; 115:460-482.
37. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008; 105:17908-17912. A recent large pivotal trial on SCIT with intralymphatic administration.
38. Krug N. Usefulness of pollen chamber in the evaluation of clinical trials with allergen products. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2006:167-170.
39. Bonifazi F, Jutel M, Bilo BM, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-1470.
40. Muller U, Golden DB, Lockey RF, Shin B. Immunotherapy for hymenoptera venom hypersensitivity. Clin Allergy Immunol 2008; 21:377-392. Latest GALEN update on SIT with hymenoptera venom.